FDAClass I · Drug · Recall D-0866-2026 · Recalled September 23, 2026

Thyroid Tablets recall — VITRUVIAS THERAPEUTICS INC

Agency report date: September 23, 2026.

1. Compare your item

This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.

Product named: Thyroid Tablets
Company / brand: VITRUVIAS THERAPEUTICS
Lot / serial / date codes: Lot # 504950, Exp Date: 09/30/2026.
Distribution: US Nationwide.

Agency product description and boundaries

Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00.

Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.

If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.

2. Agency hazard and consumer action

FDA reports: Superpotent Drug

No consumer remedy instructions are supplied in this record. Check the official notice and listed company contact for the agency’s current instructions.

Class I: most serious — reasonable probability of serious health consequences or death.

Affected product: Thyroid Tablets recall status

3. Open the official notice or contact

View the official FDA enforcement record (openFDA) ↗

Official recall ID: D-0866-2026
Brand: All VITRUVIAS THERAPEUTICS recalls
Classification: Class I
Units affected: 1955 bottles
Recall status: Ongoing
Initiated: Voluntary: Firm initiated

Affected products

Thyroid Tablets recall status

Companies & origin

Recalling firm location: Auburn, AL, United States
Firm address: 778 N Dean Rd Ste 600, N/A, 36830-4318

Identifying details (verbatim from the notice)

Product codes / lots: Lot # 504950, Exp Date: 09/30/2026.
Distribution: US Nationwide.
Firm notified the public via: Letter
FDA event ID: 99709
Recall initiated: August 21, 2026
FDA classified: September 22, 2026
FDA report date: September 23, 2026

Other drug recalls from around the same time

0 recall — B BRAUN MEDICAL INCFDA · September 16, 2026
Epinephrine Injection recall — American Regent, Inc.FDA · September 16, 2026
Dextrose Injection recall — Baxter Healthcare CorporationFDA · September 16, 2026
Glutathione 200 mg/mL recall — OPTIMAL BALANCE PHARMACYFDA · September 9, 2026
0 recall — Baxter Healthcare CorporationFDA · September 9, 2026

Verify with the official sources:

CPSC — consumer products ↗ (aggregated here)
NHTSA — vehicles, car seats, tires ↗ (aggregated here; use NHTSA's VIN lookup to check a specific vehicle)
FDA — food, drugs, medical devices ↗ (aggregated here)
USDA FSIS — meat, poultry & processed egg products ↗ (not aggregated here)
Recalls.gov — the U.S. government’s all-agency portal ↗

Found something wrong or missing? Report a data error.

Source: U.S. Food & Drug Administration. Agency excerpts come from the public data feed and may omit tables or later changes; the linked government source is authoritative. Source last checked October 22, 2026 at 12:00 PM UTC. Record retrieved October 22, 2026 at 12:00 PM UTC.

Report a data error on this page